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ABSTRACT 
The liver performs multiple functions within the human body. The liver is composed of 
numerous cell types which play important roles in organ physiology. Our study centres on the 
major metabolic cell type of the liver, the hepatocyte, and its susceptibility to damage during 
drug overdose. In these studies hepatocytes were generated from a renewable and genetically 
defined stem cell resource. In vitro derived hepatocytes were extensively profiled and 
exposed to varying levels of paracetamol and plasma isolated from liver failure patients, with 
a view to identifying non-coding micro-RNAs which could reduce drug or serum induced 
hepatotoxicity. We identified a novel anti-microRNA which reduced paracetamol induced 
hepatotoxicity and glutathione depletion. Additionally, we also demonstrated a pro-survival 
role for anti-microRNA-324 in response to plasma collected from liver failure patients. We 
believe that these studies represent an important advance for the field, demonstrating the 
power of stem cell derived systems to model human biology ‘in a dish’ and identify novel 
non-coding microRNAs which could be translated to the clinic in the future. 
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INTRODUCTION  
The liver is a multi-functional and highly regenerative organ. In both the acute and chronic 
settings liver disease has dire consequences for health. A common cause of liver damage is 
adverse reactions to drugs which can lead to drug induced liver injury (DILI). This creates 
major problems for patients, clinicians, the pharmaceutical industry and regulatory authorities 
(Olsen and Whalen, 2009). It has been reported that in the United Kingdom (UK) 
approximately 15% of the hospital in-patients suffer from liver toxicity in response to 
medicines during admissions, with 20% of these patients readmitted again after one year and 
a 2% mortality rate (Davies et al, 2009, Davies et al, 2010;). The annual cost to the National 
Health Service in the UK ~£450 million with the costs growing year by year (Pirmohamed, 
2004).  
In the context of drug overdose or serious adverse reactions, liver failure can be acute and life 
threatening, and in some cases require orthotopic liver transplantation. While transplantation 
is highly successful, such an approach has many limitations (Szkolnicka et al 2014a) and 
justifies basic science attempts to develop better human models to study liver injury and cost 
effective and scalable intervention strategies. With this in mind, we have studied the 
importance of microRNAs (miRs) in regulating human drug metabolism and their potential to 
reduce liver toxicity in response to toxic levels of paracetamol.  
miRs are small non-coding RNAs that are approximately 20 - 24 nucleotides long and their 
major function is to fine tune gene expression of target their genes. Enzyme processing of 
primary and precursor microRNAs generates a mature microRNA that is incorporated to the 
RNA-induced silencing complex (RISC). The complex recognizes the target mRNA through 
perfect and imperfect base pairing with the target miRs (Bartel, 2009). Recently, it has been 
demonstrated that microRNAs play a role in regulating the first phase of drug metabolism 
(Pan et al, 2009a; Tsuchiya et al, 2006; Yu, 2009; Yu and Pan, 2012) as well as play an 
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essential role in controlling phase III transporters important in drug efflux (Kovalchuk et al, 
2008; Zhu et al, 2008). However the second phase of drug metabolism, drug conjugation, has 
not been studied in detail. Drug conjugation is crucial in human drug metabolism, and any 
alternations in this process can lead to massive hepatocyte death and acute liver failure, 
which can be life threatening. To test the importance of miRs in regulating phase II drug 
metabolism we opted to study the metabolism of a commonly used analgesic, paracetamol. 
When taken in the appropriate amounts paracetamol is modified by sulfuryl transferases and 
UDP glucuronosyl transferases and removed from the body without organ damage (Chun et 
al, 2009). However, when paracetamol is taken above the recommended dose it is 
metabolised by phase I enzymes to generate a toxic intermediate N-acetyl-p-benzoquinone 
imine (NAPQI), which if untreated can lead to hepatocyte cell death and liver failure, placing 
the patient in a life threatening situation. In order to promote non-toxic drug metabolism, in 
the context of drug overdose, we identified and employed candidate miRs to regulate the 
different steps of paracetamol metabolism. 
In summary, we have identified a novel microRNA which regulates phase II drug metabolism 
promoting non-toxic paracetamol drug metabolism, thereby reducing hepatic cytotoxicity. 
Moreover, we demonstrate a supportive role for microRNAs in managing the toxic nature of 
human liver failure plasma. We believe our findings are novel and provide proof of concept. 
These studies exemplify the power of pluripotent stem cell derived models ‘in a dish’ to 
identify new approaches to treating human liver damage.  
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METHODS AND MATERIALS 
 
Cell Culture and Differentiation 
hESCs (H9) were cultured as described in (Hay et al, 2008; Hay et al, 2011) and maintained 
in a humidified 37 °C, 5% CO2 incubator. The cells were differentiated as described 
previously (Szkolnicka et al, 2014a; Szkolnicka et al, 2014b).  
 
Primary Human Hepatocyte Culture 
The cryopreserved human primary hepatocytes were purchased from Life Technologies. In 
this study, female line (Hu8119; HMCPIS) and male line (Hu8182; HMCPIS) were chosen. 
Both lines were donated from Caucasian patients of 21-27 years of age. The cryoplateable 
hepatocytes were plated and maintained as per vendor’s instruction. Briefly, hepatocytes 
were resuspended in thawing medium (CM3000) and plated onto matrigel in a 48-well plates. 
Subsequently, cells were placed in the incubator at 37°C (5% CO2) for 24 hours. At 24 hours 
post-replating, the medium was changed to incubation medium (CM4000). At 48 hours post-
replating, hepatocyte metabolic activity (CYP3A and CYP1A2) were measured using 
Promega luciferase-based assay.  
 
RNA Isolation and Quantitative Polymerase Chain Reaction for SULT2A1 and GSTT1 
The RNA was isolated, reversely transcribed and used for TaqMan polymerase chain reaction 
as described in Szkolnicka et al (2014a). The reference numbers of particular primers can be 
found in Supplementary Table 4.  
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RT
2
 Profiler PCR Array 
The total RNA of hESC-derived hepatocytes (day 18) and Primary Human Hepatocytes 
(purchased from 3H Biomedical AB, Sweden) was reverse transcribed using RT
2
 First Strand 
Kit (QIAGEN) as per manufacturer’s instructions. The qPCR reaction was set up using RT
2
 
Profiler PCR Array (Human Drug Metabolism Array, Human Drug Metabolism Phase II 
Enzymes Array, and Human Drug Transporters Array were purchased from QIAGEN) as per 
manufacturer’s instructions. 
 
MicroRNA Profiling 
The total RNA of hES-derived hepatocytes (day 18; n=3) and Primary Human Hepatocytes 
(purchased from 3H Biomedical AB) were analysed on Agilent miRNA platform (using 
Agilent’s SurePrint G3 Human v16 microRNA 8x60K microarray slides; miRBase version 
16.0) following Sistemic proprietary SOPs. One 100 ng of total RNA, from a working 
solution at 50ng / ul in nuclease-free water, was used as input for each microarray 
experiment. Each slide contained 8 individual arrays, each array was identified by a unique 
barcode and contained capture probes for 1349 microRNAs (1205 Human; 144 viral). The 
microarray data were normalized using Sistemic’s in-house pre-processing and data quality 
control (QC) methods. Detection calls (present or absent) for individual miRNAs were 
compared across the samples. The detection calls were calculated using the Agilent Feature 
Extraction (AFE) software version 10.7.3.1. A detailed description of how these calls are 
made is available in the Feature Extraction Reference Guide on the Agilent website 
(http://www.genomics.agilent.com) 
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MiR – mRNA Binding Analysis 
 
TargetScanHuman6.2 is an online tool that predicts microRNA binding sites at the 3’UTR of 
the biological target. The programme focuses on the presence of conserved and non-
conserved sites that match the seed region of each microRNA (Lewis et al, 2005). 
 
Immunofluorescence  
Cell cultures at day 18 of cellular differentiation were fixed in 100% ice-cold methanol at -
20°C for 30 minutes. After fixation, cell cultures were washed twice with PBS at room 
temperature. Cells were blocked with 0.1% PBS-Tween containing 10% BSA for 1 hour and 
subsequently incubated with primary antibodies diluted in PBS-0.1% Tween/1% BSA             
(the GSTT1 antibody was diluted in PBS-0.1% Tween/2% BSA)  at 4°C overnight. The 
following day, the primary antibody was removed, and the fixed monolayers were washed 
three times with PBS-0.1% Tween/1% BSA (the GSTT1 antibody was washed in PBS-0.1% 
Tween/2% BSA). Following this, the cells were incubated with the appropriate secondary 
antibody diluted in PBS for 1 hour at room temperature and washed three times with PBS. 
After washing, the Hoechst 33342 (NucBlue® Live Cell Stain Ready Probes; Life 
Technologies) diluted in PBS (as per manufacturer’s instructions) was added to the culture 
and incubated for 20 minutes at room temperature. Subsequently, the solution was removed 
and cell cultures were mounted with Mountant PermaFluor (Thermo Scientific). The cells 
were analyzed by Olympus TH4-200 microscope and Volocity 4 software. The percentage of 
positive cells and standard deviation were estimated from at least four random fields of view 
and quoted as ± standard error. The list of antibodies and dilutions are provided in 
Supplementary Table 4.  
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Paracetamol – Induced Toxicity (Toxicity Testing)  
Paracetamol (Sigma- Aldrich) was diluted in ethanol (Sigma-Aldrich) and prepared at 0.5 M 
stock concentration. Different paracetamol concentrations (0 mM, 1 mM, 2 mM, 5 mM, 10 
mM, 20mM, and 50 mM) were prepared by diluting the stock solution in specific volumes of 
HepatoZYME™ supplemented with factors (10 ng/ml HGF; 20 ng/ml OSM) and 2% Bovine 
Serum Albumin (Sigma- Aldrich). At day 17, cells were treated with specific drug 
concentration and left for 24 hours in the incubator at 37°C. At day 18 ATP production was 
measured by the CellTiter®-Glo (Promega).  For primary human hepatocytes, the cells were 
treated with the same range of paracetamol concentrations as above at 48 hours post-
replating. The concentrations were prepared by diluting the stock solution in specific volumes 
of incubation medium (CM4000) and 2% Bovine Serum Albumin (Sigma – Aldrich). Cells 
were incubated with the drug for 24 hours at 37°C. Subsequently, ATP production was 
measured by the CellTiter®-Glo (Promega). 
 
In Vitro Modulation of Paracetamol Toxicity by MicroRNAs 
At day 17, cells were transfected with scrambled controls or antagomirs to miR-24, miR-324 
for 24 hours at 37 °C. Once transfected, hESC-derived hepatocytes were exposed to the 
concentration of paracetamol resulting in 50% death (IC50) for another 24 hours. At day 19, 
the toxic effect of the drug was measured using CellTiter – Glo® Luminescent Cell Viability 
Assay (Promega) and GSH/GSSG-Glo™ Assay (Promega).  
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In Vitro Modulation of Paracetamol Toxicity by N-acetylcysteine (NAC) 
N-acetylcysteine (NAC; Sigma –Aldrich) was diluted in sterile water and prepared at 1M 
concentration. At day 17, hESC-derived hepatocytes were treated with 1mM NAC (optimal 
concentration determined from a range of 0-1.25mM) diluted in specific volumes of 
HepatoZYME™ supplemented with factors (10ng/ml HGF; 20 ng/ml OSM). At day 17, cells 
were treated with specific drug concentration and left for 24 hours in the incubator at 37°C. 
At day 18 the paracetamol toxicity was measured by the CellTiter®-Glo Luminescent Cell 
Viability Assay from Promega. 
 
Cell Viability Assay  
Cellular ATP levels were measured using CellTiter – Glo® Luminescent Cell Viability Assay 
(Promega) as per manufacturer’s instructions and the luminescence signal was detected by 
the luminometer (Promega; Madison, WI, http://www.promega.com). The IC50 (the 
concentration of the compound resulting in 50% death) of paracetamol (APAP) was 
estimated from the function f(x) = ax + b.  
 
Reduced Glutathione Depletion Assay 
The amount of reduced glutathione produced in the hESC-derived hepatocytes was measured 
by GSH/GSSG-Glo™ Assay from Promega (Madison, WI) and carried out as per the 
manufacturer’s instructions (http://http://www.promega.com/tbs/tb325/tb325.pdf). 
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Patient Information, Sample Collection, Processing 
Ethical approval for the study was from the Scotland ‘A’ Research and Ethics Committee and 
written informed consent was obtained. Three female donors or their nominated next of kin 
consented to blood sampling. Paracetamol hepatotoxicity was prospectively defined as 
previously described (Craig et al, 2013). Peripheral blood samples were obtained on the day 
of admission to the Scottish Liver Transplantation Unit. Serum was collected after 
centrifuging of blood samples at 1000 g for 15 minutes and 4 
o
C within 1 hour following 
collection, immediately aliquoted and stored and -80 
o
C until thawing for the experiments. 
Importantly, no paracetamol was detectable in the serum samples used in the study. Patient 
blood biochemistry and normal ranges are provided in Supplementary Table 5.  
 
Supplemental Information 
Supplemental information includes 5 figures and 5 tables.  
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RESULTS  
Defining Metabolic Gene Expression in Stem Cell Derived Hepatocytes. 
hESC-derived hepatocytes were produced in vitro using established methodology 
(Szkolnicka et al, 2014a, Szkolnicka et al, 2014b) and demonstrated appropriate cell 
morphology, expression of liver transcripts and displayed appreciable levels of metabolic 
function (Figure 1 A-C).  Cyp3A activity in stem cell derived hepatocytes was estimated at 
8.4% of the female and 22% of male adult hepatocytes (Figure 1C; Supplementary Figure 1). 
Whereas, Cyp1A2 activity was estimated to be 0.009% and 0.06% of female and male 
hepatocytes respectively (Figure 1C; Supplementary Figure 1).   Post validation, stem cell 
derived hepatocytes were characterised for drug metabolising gene expression using 
microarray technology. Throughout these studies, stem cell derived hepatocytes were 
compared to freshly isolated primary human hepatocytes. From these studies we 
demonstrated that stem cell derived hepatocytes expressed transcripts for phase I, II and III 
drug metabolism, albeit at reduced levels in comparison to primary hepatocytes (Figure 2; 
Supplementary Table 1).  
 
Detailed Study of Paracetamol Metabolism in Stem Cell Derived Hepatocytes. 
In order to ascertain which metabolic pathways were intact, the data from the array 
experiments were analysed using Pharma KGB software (www.pharmgkb.org). From the 
analysis we determined that a number of metabolic pathways were intact in our stem cell 
derived system, including paracetamol metabolism (Supplementary Figure 2). When 
paracetamol is taken within the therapeutic range it is metabolised and excreted normally by 
phase II and III enzymes (Supplementary Figure 2). However, if the drug is taken at higher 
doses than recommended, phase I enzymes generate N-acetyl-p-benzoquinone imine 
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(NAPQI) which is toxic and leads to glutathione depletion and ultimately cell death 
(Supplementary Figure 2). The results generated from the array experiments were validated 
by immunostaining, focussing on key phase II and phase III proteins.  Phase II enzymes from 
the non-toxic pathway, SULT2A1, and toxic pathway, GSTT1, were expressed in 59% and 
~98% cells respectively (Figure 3A; Supplementary Table 1).  Importantly, stem cell derived 
hepatocytes also expressed phase III drug transporters important in each pathway. 
Approximately 52% and 77% of cells expressed ABCG2 and ABCC1 respectively (Figure 
3A; Supplementary Table 1).      We therefore hypothesised that stem cell derived 
hepatocytes possessed the correct machinery to process paracetamol in a non-toxic and toxic 
manner (Figure 3B). To test this we exposed stem cell derived hepatocytes to a range of 
concentrations of paracetamol, ranging from 0 to 50 mM. Following exposure, cell viability 
was monitored by ATP production. From these studies we demonstrated that stem cell 
derived hepatocyte cell death increased in a dose dependent fashion with an IC50 value of 
12.85 mM. Although differences in cytochrome P450 metabolic capacity were identified 
between stem cell derived hepatocytes and primary hepatocytes, the paracetamol IC50 values 
obtained in vitro were comparable to both female and male hepatocytes, 10.51 mM and 12.6 
mM respectively (Supplementary Figure 3).  
 
Identification of Novel MicroRNAs Within Stem Cell Derived Hepatocytes 
Once we had established that stem cell derived hepatocytes responded to paracetamol 
appropriately, we wished to study microRNA (miR) expression within stem cell derived 
hepatocytes. miRs are known to be potent regulators of gene expression, and our hypothesis 
was that miRs could play an important role in modulating paracetamol metabolism and 
therefore drug overdose in hepatocytes. To screen for miRs which regulate this process, day 
18 hESC-derived hepatocytes were harvested and analysed using Agilent miRNA platform. 
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From these studies we determined that stem cell derived hepatocytes and primary human 
hepatocytes expressed 367 miRs in common, with 220 miRs being expressed at similar levels 
and 147 miRs differentially expressed (Figure 4A and B; Supplementary Table 2). Of note, 
the major miR expressed in the liver, miR-122, was expressed at similar levels between 
primary and hESC derived hepatocytes (Figure 4C). Next, we evaluated similarly expressed 
miRs using TargetScanHuman6.2 (www.targetscan.org) to predict novel miRs which may 
regulate phase II enzymes important in paracetamol metabolism. The ‘hits’ from our screen 
were ranked based on the predicted efficacy using the context + scores (Friedman et al, 2009 
and Grimson et al, 2007). Our analysis predicted that miR 24 and 324 could potentially 
regulate GSTT1 and SULT2A1 respectively, and those miRs served as the focus of further 
experimentation (Supplementary Table 3). 
 
MicroRNA 324 Regulates Paracetamol Induced Toxicity in Stem Cell Derived Hepatocytes 
In order to test our hypothesis that stem cell derived hepatocyte susceptibility to paracetamol 
overdose could be regulated by miRs, we transfected synthetic inhibitory non-coding RNAs. 
Stem cell derived hepatocyte transfection was optimised and miRs and antagomirs were used 
at a concentration of 50 nM for 24 hours prior to incubation with a toxic dose of paracetamol. 
In order to examine the effects of antagomir transfection on phase II enzyme expression, we 
performed qPCR and immunostaining. hESC-derived hepatocytes transfected with the 
scrambled control served as our baseline throughout. In response to transfection with the 
antagomir for miR 324, stem cell derived hepatocytes expressed greater SULT2A1 gene and 
protein expression. (Figure 5A and B). In contrast, transfection with miR-324 or the non-
coding RNAs for miR-24 did not result in gene expression changes, nor dramatic alterations 
in cell viability and reduced glutathione levels (Supplementary Figures 4 and 5). Once we 
had established that SULT2A1 expression could be modulated successfully, we measured cell 
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viability in response to a 50% toxic dose of paracetamol for 24 hours, by measuring ATP 
depletion (IC50). The fold increase in cell viability was comparable with the cell viability 
enhanced by N-acetylcysteine (NAC) (Figure 5C). Notably increased cell viability was 
paralleled by a two fold increase in reduced glutathione levels (Figure 5D). 
MicroRNA 324 Reduces Cell Necrosis in Response to Plasma from a Patient With 
Fulminant Hepatic Failure. 
Following on from acute paracetamol induced hepatocyte injury, we studied the toxic nature 
of patient’s derived plasma on stem cell derived hepatocytes. As before stem cell derived 
hepatocytes were differentiated and transfected with either the scrambled control or the 
antagomir for miR-324. Twenty four hours post transfection, stem cell derived hepatocytes 
were incubated with human plasma from three female donors (anonymised patient details and 
blood biochemistry is supplied in Supplementary Table 5). Following exposure to plasma, 
stem cell derived hepatocyte ATP levels were measured. Notably, stem cell derived 
hepatocytes transfected with antagomir 324 displayed greater levels of ATP which was 
significantly increased over scrambled controls in two out of three patients (Figure 6A). In 
line with ATP, we also measured caspase 3 and 7 activity in stem cell derived hepatocytes. 
As for ATP, we also observed a significant increase in caspase activity following transfection 
with antagomir 324 in two out of three patients (Figure 6B). Taken together these data 
suggest that increasing the levels of SULT2A1 gene expression redirected cell necrosis to 
apoptosis, following challenge with plasma from patient with fulminant hepatic failure. 
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DISCUSSION 
Despite major progress in the knowledge and management of human liver injury, there are 
approximately 2000 cases per year of acute liver failure (ALF) in the United States 
(Hoofnagle, 1995; Polson et al 2005; Fontana, 2008). Paracetamol overdose is a major cause 
of ALF, with critical damage done to the hepatocyte compartment of the liver, and accounts 
for approximately 50% of cases (Nourjah et al, 2006; Bari and Fontana, 2014). Although 
hepatocyte cell death occurs in large numbers, the manner by which the cells die following 
overdose remains complicated and controversial (Jaeschke et al 2012).  
 
The hepatotoxic dose of paracetamol is considered to be greater than 75mg/kg. This translates 
into toxic blood concentrations that range between 25-150 mg/l (Winek, 1994 and Dollery, 
1993). Currently, treatment with N-acetylcysteine (NAC) is the most effective strategy in 
treating paracetamol-induced liver injury. Patients that have ingested 75-150 mg/kg/24h can 
be considered for NAC treatment, with NAC usually prescribed if  > 150mg/kg was ingested 
within 24 hours (based on the guidelines issued by the National Poisons Information Service 
UK; www.npis.com). Although successful, oral and intravenous NAC treatment may elicit 
serious side effects (Harrison et al, 1990; Bailey and McGuigan, 1998; Appleboam et al, 
2002; Pakravan et al, 2008) and therefore new approaches to treat acute intoxication are 
necessary. In order to study the important nature of microRNAs in human drug toxicity, 
reliable and renewable liver models are required. In this vein, we have employed pluripotent 
stem cells to generate human hepatocyte like cells. The in vitro model employed in these 
studies is serum free and has already which has demonstrated promise in modelling human 
drug metabolism and toxicity testing (Szkolnicka et al, 2014a; Szkolnicka et al, 2014b; 
Medine et al, 2013; Zhou et al, 2014, Cameron, et al 2015). Moreover, in these studies we 
Page 16 of 65
ScholarOne Support: (434) 964-4100
Stem Cells Translational Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
17 
 
support those observations as stem cell derived hepatocytes display similar IC50 values to 
male and female primary hepatocytes (Supplementary Figure 3).  
 
MicroRNAs are potent non-coding RNAs which can alter mammalian gene expression and 
therefore represent promising candidates for modulating enzymatic pathways (Pan et al, 
2009a; Tsuchiya et al, 2006; Yu, 2009; Yu et al, 2010; Yu and Pan, 2012; Kovalchuk et al, 
2008; Zhu et al, 2008) and treating human disease. Several studies have shown that 
regulation of different microRNAs may potentially serve as effective therapeutics (Thong et 
al, 2014; Heidet and Gubler, 2009, Daige et al, 2014). In the recent years there has been a 
focus on miR regulation of phase I enzymes involved in human drug metabolism. Studies 
have demonstrated that miR-27b regulates CYP3A4 and CYP1B1 and miR-126* controls 
CYP2A3 expression (Pan et al, 2009a; Tsuchiya et al, 2006; Kalscheuer et al, 2008). Other 
studies have also focused on microRNA regulation of drug transporters such as P-
glycoprotein and breast cancer resistant protein (Kovalchuk et al, 2008; Zhu et al, 2008; Liao 
et al, 2008; To et al, 2008, Pan et al, 2009b). While phase I and phase III of drug metabolism 
have been studied, there is still little known about regulation of phase II enzymes by 
microRNAs. Phase II enzymes, such as glutathione-s-transferases (GSTs) and 
sulfotransferases (SULTs), are essential to sufficiently detoxify different xenobiotics, 
therefore these enzymes serve as important clinical targets.         In order to test whether 
microRNAs could potentially regulate phase II enzymes (SULT2A1 and GSTT1) that play an 
important role in paracetamol metabolism, we used TargetScan Human software to determine 
precise miR-gene binding interactions and used lipofectamine-based transfection to examine 
their supportive effects. Inhibition of miR-324-5p in hESC-derived hepatocytes resulted in 
increased SULT2A1 expression (Figure 5A and 5B). This led to improved cell survival in 
vitro, in a matter comparable with current clinical practice, NAC administration (Figure 5C). 
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Notably, the inhibition of miR-324-5p was paralleled by an increase in reduced glutathione 
production (Figure 5D). In contrast, inhibition of miR-24-3p did not have any effect on 
GSTT1 expression, cell viability and reduced glutathione production in the paracetamol 
studies. Although TargetScan has been widely used, and is considered to be the most 
effective in predicting miR-target binding sites (Baek et al, 2008; Witkos et al, 2011), 
algorithm prone errors may have led to this false prediction.  
 
Given the promising effects of the antagomir 324 delivery in response to paracetamol, we 
were keen to assess its efficacy after exposure to liver failure serum from paracetamol 
poisoned female patients. Importantly, paracetamol was not present in patient sera and 
therefore we were studying the supportive effects of antagomir 324 in the context of patient 
recovery. The inhibition of miR-324-5p, by antagomir 324,  resulted increased cell viability 
and caspase activity in 2 patients (Figure 6) suggesting a potential switch from cell necrosis 
to apoptosis. Contrary to these two patients, antagomir 324 did not have any rescue effect 
after exposure to the third patient’s serum. The exact reason for this is unknown, however, 
this patient possessed the lowest concentration of ALT which may have reflected a lesser 
liver injury and therefore lower toxic load to the cells (Supplementary Table 5).  
 
In conclusion, we demonstrate that a novel miR inhibitor, antagomir 324, plays a major role 
in the regulation of SULT2A1, improving cell survival in the context of acute injury and 
patient recovery following paracetamol overdose. We believe that these studies are novel and 
offer serious promise to reduce the toxic effects of paracetamol overdose. 
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FIGURE LEGENDS 
Figure 1: Stagewise human embryonic stem cell (hESC) differentiation to the hepatocyte 
lineage. (A) Phase-constrast imaging demonstrated that cells underwent sequential 
morphological changes during transit from stem cell (day 0), to definitive endoderm (day 3), 
to hepatoblast (day 10), to hepatocyte (day 18). (B) Immunocytochemistry demonstrating 
upregulation of HNF4a and albumin during hepatic specification at day 18. Negative controls 
performed with corresponding immunoglobulin G (IgG). The percentage of positive cells is 
provided in the top right of each panel. This was calculated from four random fields of view 
and is quoted as ± standard error. (C) Cyp3A and Cyp1A2 metabolism were measured in day 
18 hepatocyte like cells using the Promega pGlo system
TM
. Experiments were performed in 
triplicate and measured on a luminometer. The units of activity quoted are relative light units 
per millilitre of supernatant per milligram of protein (RLU/mg/ml).  The scale for all images 
represent 100 um. Abbreviations: HNF4a, hepatocyte nuclear factor 4a; ALB, Albumin.  
Figure 2: Stem cell –derived (day 18) and primary human hepatocyte gene expression. The 
scatter plots represent expression of the major metabolic genes involved in Phase I, Phase II, 
and Phase III drug metabolism. Gene expression was performed using Human Drug 
Metabolism RT
2
 Profiler PCR Array (QIAGEN) according to the manufacture’s instructions. 
The gene expression was analysed by RT2 Profiler PCR Array Data Analysis version 5.0 
(QIAGEN). The scatter plot represents 3 fold change in gene expression. The graph plots the 
log10 of normalized gene expression levels in a control condition, primary human 
hepatocytes (x-axis) versus an experimental condition, hESC-derived hepatocytes (y-axis). 
Symbols outside the boundary area indicate fold –differences larger than a threshold (3 fold).  
The red symbols in the upper - left corner readily identify up-regulated genes, and the green 
symbols in the lower-right corner readily identify down-regulated genes. The human primary 
hepatocyte total RNA was purchased from 3H Biomedical (Sweden).  
Figure 3: The expression of enzymes and transporters involved in paracetamol (APAP) 
metabolism. (A) The panel represents protein expression of phase II enzymes GSTT1, 
SULT2A1 and Phase III transporters ABCC1, ABCG2 in stem cell – derived hepatocytes. 
The percentage of positive cells is provided in the top right of each panel. This was calculated 
from four random fields of view and is quoted as ± standard error. The images were taken at 
x 20 magnification. Scale bar represents 100 um. (B) Phase II enzymes (GSTT1, SULT2A1) 
and Phase III transporters (ABCG2, ABCC1) play major role in a toxic and non-toxic 
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pathways of paracetamol metabolism. In the non-toxic pathway paracetamol is metabolised 
by SULT2A1 enzymes to produce APAP sulfate metabolite that is effluxed from the cell by 
ABCG2 transporter. In a toxic pathway, paracetamol is metabolised by GSTT1 enzyme to 
produce APAP cysteine (mercapturic acid) metabolite that is effluxed from the cell by 
ABCC1 transporter. Abbreviations: GSTT1, glutathione-S-transferase theta 1; SULT2A1, 
sulfotransferase 2A1; ABCG2, ATP-Binding Cassette Transporter Subfamily G member 2; 
ABCC1,  ATP-Binding Cassette Transporter Subfamily  C member 1.  
Figure 4: hESC-derived hepatocytes (hESC-heps) and primary human hepatocytes (PHH) 
microRNA expression profile. (A) Principle Component Analysis overview plot demonstrates 
strong clustering by cell type. (B) Statistical analysis of the microRNA Array demonstrates 
367-reliably detected microRNAs in both hESC-heps and PHH; 220 microRNAs have a 
similar expression in both systems, and 147 microRNAs are differentially-expressed. (C) 
microRNA 122 (miR-122) is expressed in hESC-heps at the same level as in PHH. The 
microRNA Array was carried out by Sistemic Limited. The RNA samples (4 replicates of 
PHH and 4 experimental samples of hESC-derived hepatocytes) were run on Agilent miRNA 
platform. 
Figure 5: Antagomir of microRNA 324 upregulated SULT2A1 gene and protein expression 
and increased cell survival after exposure to paracetamol. At day 17, hESC-heps were 
transfected with the antagomir of the corresponding microRNA at 50 nM for 24 hours. 
Transfection with the Ant-324-5p upregulated SULT2A1 gene expression by 2-fold (A) and 
protein expression by 20% (B) in comparison with the scrambled control. At day 17, hESC-
hepatocytes were either transfected with antagomirs or treated with 1 mM N-acetylcysteine 
(NAC) concentration for 24 hours. At day 18, the the antagomir transfected or NAC pre-
exposed hESC-hepatocytes were exposed to paracetamol concentration that causes 50% of 
the cell death (IC50 = 12.85 mM) for another 24 hours. At day 19, the cell viability was 
measured using CellTitre Assay (Promega) and Glutathione Depletion Assay (Promega). The 
antagomir of microRNA 324 (Ant 324) significantly increased ATP to the levels comparable 
with NAC (fold increase was calculated in comparison with control; the values for Ant ctrl = 
2.17 x 10
8
; Ant 324= 3.12 x 10
8
; H2O (vehicle) = 2.38 x 10
8
; NAC = 3.86 x 10
8
 (C) and 
enhanced reduced glutathione levels (D). Levels of significance were measured by Student’s t 
test. Significance levels are denoted by one asterisks to indicate p < 0.05. The percentage of 
positive cells is provided in the top right of each panel. This was calculated from four random 
fields of view and is quoted as ± standard error. The scale bar represents: 100 um. 
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Abbreviations: SULT2A1, sulfotransferase 2A1; Ant Control; Scrambled Antagomir Control; 
Ant 324; Antagomir 324-5p. Levels of significance were measured by Student’s t test. 
Significance levels are denoted by one asterisk to indicate p < 0.05. 
Figure 6: hESC-derived hepatocytes transfected with the antagomir to miR-324-5p. Twenty 
four hours post transfection hESC-hepatocytes were exposed to the plasma from patients with 
fulminant hepatic failure for a further twenty four hours (Patients 1, 8 and 58). ATP levels 
and caspase 3/7 activation were determined using Promega Glo technology and measured on 
a luminometer (Promega). Units of activity are expressed as relative light units (RLU) ml
-1 
(n=4). Levels of significance are quoted and measured by Student’s t-test. Significance levels 
are denoted by one and two asterisks to indicate p < 0.05 and p < 0.01 respectively. 
Supplementary Figure 1: Metabolic activity of female and male primary human 
hepatocytes. Cyp3A and Cyp1A2 metabolism were measured in both lines 48 hours post-
replating using the Promega pGlo system
TM
. Experiments were performed in triplicate and 
measured on a luminometer. The units of activity quoted are relative light units per millilitre 
of supernatant per milligram of protein (RLU/mg/ml).   
Supplementary Figure 2: Paracetamol (APAP) metabolism (based on Pharmacogenomics 
Knowledge Base PharmGKB; www.pharmgkb.org). At normal doses APAP is metabolised 
by two major families of phase II enzymes: Sulfotransferases (SULTs) and UDP-
glucuronosylltransferases (UGTs). This leads to the production of two metabolites: APAP-
sulfate and APAP-glucuronide, which are further effluxed from the cell by one of the ABC 
transporters. At higher doses than recommended, paracetamol is metabolised by Cytochrome 
P450 enzymes. This leads to the formation of a reactive metabolite, N-acetyl-p-
benzoquinoneimine (NAPQI), which is further transformed  to a non-toxic  APAP- cysteine 
by Glutathione –S- transferases (GSTT1,GSTP1). The metabolite is effluxed from the cell by 
one of the phase III transporters.  
Supplementary Figure 3: Paracetamol in vitro toxicity in stem-cell derived hepatocytes              
(hESC-heps) and primary human hepatocytes (PHH). hESC-heps (at day 17) and PHH (24 
hours post- replating) were induced with different concentrations of paracetamol (0-50 mM) 
for 24 hours. The CellTitre viability assay (Promega) was used to measure the ATP levels.    
The IC50 was calculated from the function f(x)= ax + b.   
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Supplementary Figure 4: At day 17, hESC-heps were transfected with the antagomir of the 
corresponding microRNA at 50 nM concentration for 24 hours.  Transfection with the 
antagomir of microRNA 24-3p did not have any effect either on gene (A) or protein (B) 
expression of GSTT1.  At day 18, the transfected hESC-heps were exposed to paracetamol 
concentration that causes 50% of the cell death (IC50 = 12.85 mM) for another 24 hours. At 
day 19, the cell viability was measured using CellTitre Assay (Promega) and Glutathione 
Depletion Assay (Promega). The Ant-24 decreased cell viability (C) and reduced glutathione 
(D) after exposure to paracetamol comparing to the scrambled control. The percentage of 
positive cells is provided in the top right of each panel. This was calculated from four random 
fields of view and is quoted as ± standard error. The scale bar represents: 100 um. 
Abbreviations: Ant Control; Scrambled Antagomir Control; Ant 324; Antagomir 324-5p.  
Supplementary Figure 5:  At day 17, hESC-derived hepatocytes were transfected with 
precursors at 50nM concentration for 24 hours. At day 18, cells were exposed to paracetamol 
(APAP) concentration that causes 50% of the cell death (IC50 = 12.85 mM) for 24 hours. At 
day 19, the cell viability and glutathione reduction were measured using CellTiter – Glo® 
Luminescent Cell Viability Assay (Promega) and GSH/GSSG – Glo™ Assay (Promega) 
respectively. Abbreviations: Pre; precursor. Pre ctrl/Pre 24/Pre 324, precursor scrambled 
control/ precursor of miR -24/ precursor of mi  -324-5p. Levels of significance are quoted 
and measured by Student’s t-test. Significance levels are denoted by one asterisks to indicate 
p < 0.05. 
Supplementary Table 1: Fold-Change (2^(- Delta Delta Ct)) is the normalized gene 
expression (2^(- Delta Ct)) in the Test Sample divided the normalized gene expression (2^(- 
Delta Ct)) in the Control Sample. Fold-Regulation represents fold-change results in a 
biologically meaningful way. Fold-change values greater than one indicate a positive- or an 
up-regulation, and the fold-regulation is equal to the fold-change. Fold-change values less 
than one indicate a negative or down-regulation, and the fold-regulation is the negative 
inverse of the fold-change. Up-regulated genes (fold differences larger than a 3 fold 
threshold) are indicated in red, down-regulated genes (fold differences narrower than 3 fold 
treshold) are indicated in green. Genes similarly expressed for the Group 1 and Control (fold 
differences between -3 to +3 boundary) are indicated in black. Abbreviations: HLC, 
hepatocyte-like-cells; PHH, primary human hepatocytes. 
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Supplementary Table 2: The list of 220 microRNAs commonly expressed in stem cell – 
derived hepatocytes (day 18) and primary human hepatocytes (PHH). The RNA samples (4 
replicates of PHH and 4 experimental samples of hESC-derived hepatocytes) were analysed 
on the Agilent miRNA platform (using Agilent’s SurePrint G3 Human v16 microRNA 
8x60K microarray slides; miRBase version 16.0. 
Supplementary Table 3: Predicted microRNA/mRNA binding site by TargetScanHuman5.2 
(www.targetscan.com). (A) Human microRNA hsa-miR-324-5p has been predicted to bind 
its target gene SULT2A1 at the 3’ untranslated region at position between 639-645 nt.  
Human microRNA has-miR-24-3p has been predicted to bind its target gene GSTT1 at the 3’ 
untranslated region at position between 266-272 nt. (B) The table represents type of seed 
match and context score for each of the microRNA/mRNA binding. (C) The table represents 
the miRBase accession number of each of the selected microRNAs and UniGene and 
GeneBank of selected genes of interest. Abbreviations: SULT2A1, sulfotransferase 2A1; 
GSTT1, glutathione-s-transferase theta 1. 
Supplementary Table 4: The table demonstrates qPCR primers, and primary/secondary 
antibodies used in this study.  
Supplementary Table 5: Anonymised patient details. (A) The table represents the plasma 
contents of each of the patients used in this study. (B) The table represents normal ranges for 
particular sera and international normalized ratio (INR). ALT and BILI are liver function 
tests. Creatinine is a measure of renal function, which is often compromised in liver 
disease INR is International Normalized Ratio of the prothrombin time, a coagulation 
function test. 
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Supplementary Table 1 
RT
2
 PROFILER PCR ARRAY - Human Drug Metabolism Phase I (QIAGEN; PAHS-002Z) 
Gene 
Symbol 
AVG ΔCt 2^ - ΔCt 
Fold 
Change 
Fold Up – or Down- 
Regulation               
Group1 
(HLC) 
Control 
Group 
(PHH) 
Group1 
(HLC) 
Control 
Group 
(PHH) 
Group  1/ 
Control 
Group 1/ Control 
CYP1A1 0.38 7.02 0.768483 0.007705 99.74 99.74 
ADH4 4.08 6.10 0.059302 0.014562 4.07 4.07 
ADH5 1.01 2.39 0.495439 0.190431 2.60 2.60 
EPHX1 1.64 1.52 0.321538 0.347956 0.92 -1.08 
ADH6 4.78 3.34 0.036387 0.098713 0.37 -2.71 
ALDH1A1 0.45 -0.45 0.729565 1.363349 0.54 -1.87 
CYPB5R 0.65 -0.38 0.636322 1.303635 0.49 -2.05 
CYP2B6 7.46 6.75 0.005694 0.009309 0.61 -1.63 
CYP3A5 2.01 -1.18 0.248204 2.272074 0.11 -9.15 
CYP2J2 6.06 1.98 0.015040 0.252693 0.06 -16.80 
CYP2C8 6.76 0.63 0.009224 0.647110 0.01 -70.16 
CYP2C9 7.46 -0.49 0.005694 1.402808 0.00 -246.36 
CYP3A4 7.46 1.34 0.005694 0.394672 0.01 -69.31 
CYP2C19 6.91 2.15 0.008323 0.225670 0.04 -27.11 
CYP2D6 7.09 4.56 0.007318 0.042426 0.17 -5.80 
CES1 4.46 -1.36 0.045546 2.559360 0.02 -56.19 
CES2 4.07 -0.66 0.059552 1.579842 0.04 -26.53 
ADH1B 6.89 4.26 0.008442 0.052291 0.16 -6.19 
ADH1C 7.46 4.16 0.005694 0.056056 0.10 -9.84 
 
 
 
 
 
 
 
 
 
 
RT2 PROFILER PCR ARRAY - Human Drug Metabolism Phase II (QIAGEN; PAHS-069Z) 
Gene 
Symbol 
AVG ΔCt 2^ - ΔCt 
Fold 
Change 
Fold Up – or Down- 
Regulation               
Group1 
(HLC) 
Control 
Group 
(PHH) 
Group1 
(HLC) 
Control 
Group 
(PHH) 
Group  1/ 
Control 
Group 1/ Control 
GSTP1 -0.20 4.85 1.148277 0.034646 33.14 33.14 
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Supplementary Table 1 
GSTA1 -0.42 2.08 1.341208 0.236264 5.68 5.68 
GSTA4 3.37 6.86 0.096681 0.008588 11.26 11.26 
GSTA3 6.20 8.55 0.013622 0.002677 5.09 5.09 
SULT1E1 3.85 9.74 0.069583 0.001166 59.66 59.66 
SULT1A2 4.37 7.98 0.048511 0.003948 12.29 12.29 
SULT1C2 8.20 12.73 0.003411 0.000147 23.14 23.14 
SULT1C3 8.20 12.73 0.003411 0.000147 23.14 23.14 
SULT1C4 6.63 8.40 0.010075 0.002967 3.40 3.40 
NAT 1 9.80 11.43 0.001118 0.000362 3.09 3.09 
GSTO1 0.04 0.46 0.971041 0.724547 1.34 1.34 
GSTO2 8.00 7.95 0.003893 0.004040 0.96 -1.04 
GSTT1 3.47 3.39 0.089944 0.095282 0.94 -1.06 
GSTK1 2.45 2.52 0.182812 0.174788 1.05 1.05 
GSTM4 6.98 7.30 0.007905 0.006338 1.25 1.25 
UGT2B28 2.98 2.15 0.126827 0.225954 0.56 -1.78 
UGT3A1 7.78 6.94 0.004559 0.008118 0.56 -1.78 
SULT1A1 3.08 3.96 0.117951 0.064148 1.84 1.84 
SULT2A1 4.55 3.61 0.042611 0.081891 0.52 -1.92 
COMT 2.01 2.76 0.249051 0.147120 1.69 1.69 
UGT1A1 6.58 4.83 0.010486 0.035145 0.30 -3.35 
UGT1A4 10.39 3.28 0.000746 0.102607 0.01 -137.61 
UGT2B4 8.36 3.41 0.003054 0.093826 0.03 -30.73 
UGT2B7 3.56 0.83 0.084852 0.564152 0.15 -6.65 
UGT2B10 8.65 5.59 0.002489 0.020726 0.12 -8.33 
UGT2A3 10.59 4.69 0.000649 0.038640 0.02 -59.49 
UGT2B17 10.85 4.95 0.000543 0.032289 0.02 -59.46 
NAT2 7.58 5.64 0.005230 0.020051 0.26 -3.83 
SULT1B1 8.60 5.59 0.002579 0.020766 0.12 -8.05 
 
 
RT
2
 PROFILER PCR ARRAY - Human Drug Transporters Phase III (QIAGEN; PAHS-070Z) 
Gene 
Symbol 
AVG ΔCt 2^ - ΔCt 
Fold 
Change 
Fold Up – or Down- 
Regulation               
Group1 
(HLC) 
Control 
Group 
(PHH) 
Group1 
(HLC) 
Control 
Group 
(PHH) 
Group  1/ 
Control 
Group 1/ Control 
ABCC1 6.89 8.73 0.008423 0.002350 3.58 3.58 
ABCC4 4.89 9.01 0.033689 0.001934 17.42 17.42 
ABCC5 5.93 8.98 0.016410 0.001982 8.28 8.28 
ABCG2 4.52 9.39 0.043502 0.001491 29.17 29.17 
SLCO1A2 7.29 11.41 0.006390 0.000368 17.38 17.38 
SLCO2A1 6.64 12.26 0.009994 0.000204 49.01 49.01 
SLC19A3 4.75 7.85 0.037173 0.004328 8.59 8.59 
SLC22A7 8.55 11.07 0.002659 0.000466 5.70 5.70 
SLC22A9 6.43 8.37 0.011561 0.003030 3.82 3.82 
ABCC3 5.53 3.98 0.021683 0.063471 0.34 -2.93 
ABCB11 8.58 9.07 0.002616 0.001859 1.41 1.41 
ABCG8 8.74 7.25 0.002338 0.006587 0.35 -2.82 
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Supplementary Table 1 
SLC19A1 9.35 10.40 0.001529 0.000738 2.07 2.07 
SLC19A2 4.95 6.46 0.032350 0.011345 2.85 2.85 
SLC22A3 6.28 6.05 0.012855 0.015105 0.85 -1.18 
ABCB1 8.16 5.09 0.003490 0.029260 0.12 -8.38 
ABCB4 8.73 6.51 0.002351 0.011003 0.21 -4.68 
ABCC2 6.42 2.84 0.011709 0.139434 0.08 -11.91 
SLCO1B1 10.59 6.34 0.000648 0.012367 0.05 -19.09 
SLCO1B3 10.88 7.76 0.000532 0.004626 0.12 -8.69 
SLC22A1 11.12 7.00 0.000448 0.007829 0.06 -17.46 
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MICRORNAs COMMONLY EXPRESSED IN PRIMARY HUMAN HEPATOCYTES AND hESC - DERIVED HEPATOCYTES
miRNA Mean log2 intensity Relative mean intensity (%) Max. log2 intensity
hsa-let-7b-3p 2.167553914 15.39758566 4.759083184
hsa-let-7e-5p 4.315044314 30.65264676 5.195762764
hsa-let-7f-1-3p 1.45060131 10.30459164 3.752587461
hsa-miR-1 1.562493903 11.09943959 4.033989956
hsa-miR-107 8.445884654 59.99676945 9.20038125
has-miR-1202 6.624326485 47.05702306 9.080396756
hsa-miR-1207-5p 8.276057831 58.79037591 10.36982484
hsa-miR-122-5p 10.08319276 71.62766441 12.88839682
hsa-miR-1224-5p 4.619021262 32.8119984 6.317471652
hsa-miR-1225-3p 3.997769591 28.39883213 5.235933105
hsa-miR-1225-5p 7.302618353 51.87538401 9.080396756
hsa-miR-1226* 2.73590075 19.4349335 6.432835079
hsa-miR-1228-3p 4.737513176 33.65372574 6.047606994
hsa-miR-1228-5p 2.336520334 16.59786719 5.533498506
hsa-miR-1234 5.018803171 35.65191678 6.517331819
hsa-miR-1237 3.113032203 22.11395052 4.222428371
hsa-miR-1238 4.283605841 30.42931826 5.402617074
hsa-miR-1246 9.203731352 65.38026159 12.88839682
hsa-miR-1249 1.710712988 12.15233891 3.779902166
hsa-miR-1258 1.366140729 9.704611618 3.652512778
hsa-miR-125a-3p 3.718808154 26.4171824 5.533498506
hsa-miR-125b-5p 6.907149701 49.06610558 8.24897089
hsa-miR-126-3p 4.453699943 31.63761046 6.745973602
hsa-miR-1260b 8.739559616 62.08293919 9.951193434
hsa-miR-1268b 6.897900491 49.00040226 8.914241059
hsa-miR-1275 7.082825486 50.31404822 9.543230472
hsa-miR-128 4.867008714 34.57361919 5.863396753
hsa-miR-1281 4.906137632 34.85157807 7.000447289
hsa-miR-1288 3.126365697 22.20866726 4.382662349
hsa-miR-1290 6.649179186 47.23356842 9.685937919
hsa-miR-1296 1.866800635 13.2611339 3.836693986
hsa-miR-1305 4.957477645 35.21628054 6.488825654
hsa-miR-133b 1.767910763 12.55865298 4.191590285
hsa-miR-135a-3p 3.580095563 25.43181406 5.333142011
hsa-miR-140-5p 3.713856714 26.38200901 5.333142011
hsa-miR-1471 2.371194554 16.84418138 5.108433596
hsa-miR-148a-3p 7.715908631 54.81126137 9.34381318
hsa-miR-148b-3p 5.16186919 36.66821043 6.317471652
hsa-miR-150-3p 4.834592275 34.34334353 7.181437537
hsa-miR-151a-3p 4.160489957 29.55474376 5.468096887
hsa-miR-151a-5p 6.759415776 48.01665268 7.908331533
hsa-miR-155-5p 2.817584404 20.01518714 4.174217694
hsa-miR-16-5p 8.507873725 60.4371193 9.685937919
hsa-miR-17-3p 3.717872965 26.41053913 5.605092098
hsa-miR-181a-5p 6.125048032 43.51031416 7.000447289
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hsa-miR-181b-5p 4.149834728 29.47905254 4.97754762
hsa-miR-1825 4.717609699 33.51233803 6.609645511
hsa-miR-183-5p 3.26200335 23.17219225 5.2540446
hsa-miR-185-5p 3.599703802 25.5711045 4.964394851
hsa-miR-186-5p 3.107641947 22.07565993 4.576235395
hsa-miR-188-5p 5.832657074 41.43326556 9.2666837
hsa-miR-1909-5p 1.881355523 13.36452701 4.082699416
hsa-miR-191-3p 4.106883242 29.1739394 4.949522624
hsa-miR-1910 1.56203899 11.09620803 4.204958561
hsa-miR-1914-3p 4.204836624 29.8697678 5.120226753
hsa-miR-1915 8.285328163 58.85622928 10.65447387
hsa-miR-193a-5p 4.085079479 29.01905268 5.605092098
hsa-miR-197-3p 5.426277098 38.5464767 7.888192297
hsa-miR-1973 5.804181369 41.23098357 6.891326276
hsa-miR-198 2.236101149 15.88452253 5.2540446
hsa-miR-203 3.126895637 22.21243177 4.798541198
hsa-miR-205-3p 1.96851625 13.98368797 4.713406887
hsa-miR-20a-3p 2.765103481 19.64238003 4.366871399
hsa-miR-21-5p 12.09963664 85.95181434 12.88839682
hsa-miR-210 5.877366952 41.75086974 8.351444508
hsa-miR-211-5p 1.376709151 9.779686194 3.768765425
hsa-miR-218-5p 4.947405224 35.14472939 7.814426908
hsa-miR-22-5p 2.71668992 19.29846611 4.156098562
hsa-miR-221-3p 4.988289183 35.43515551 6.047606994
hsa-miR-224-5p 4.216325184 29.95137874 5.863396753
hsa-miR-2276 2.831064559 20.1109457 5.567690079
hsa-miR-23a-3p 8.369316464 59.45285437 9.2666837
hsa-miR-23b-3p 7.84616685 55.73657265 9.20038125
hsa-miR-24-3p 8.311629805 59.04306744 9.166945457
hsa-miR-25-3p 6.685005927 47.48806973 8.159537635
hsa-miR-26a-5p 7.010850118 49.80275903 8.782112163
hsa-miR-26b-5p 7.887656757 56.03130322 9.20038125
hsa-miR-27a-3p 7.070116486 50.22376769 8.24897089
hsa-miR-27b-3p 7.760195925 55.12586365 9.34381318
hsa-miR-28-5p 4.614680979 32.78116647 6.020154252
hsa-miR-2861 8.098232261 57.52716191 11.77690063
hsa-miR-30a-3p 2.950765003 20.96125804 4.534663185
hsa-miR-30a-5p 6.145492589 43.65554553 7.458327192
hsa-miR-30b-5p 6.546012759 46.50070827 7.941037626
hsa-miR-30c-5p 4.341174699 30.83826837 5.716816843
hsa-miR-30e-3p 2.959039546 21.02003765 4.481761629
hsa-miR-30e-5p 5.432525493 38.59086323 6.891326276
hsa-miR-31-3p 1.917007372 13.61778595 3.803379697
hsa-miR-31-5p 2.482850148 17.63734577 5.235933105
hsa-miR-3124-5p 1.762034727 12.51691157 4.011269468
hsa-miR-3125 3.744020805 26.59628473 5.090800321
hsa-miR-3127-5p 3.293369985 23.39501045 5.834190844
hsa-miR-3137 2.024382356 14.38054229 4.097587661
hsa-miR-3138 2.135530188 15.17009971 4.393786163
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hsa-miR-3141 5.767174081 40.96809605 8.494581071
hsa-miR-3148 2.369747636 16.83390295 4.222428371
hsa-miR-3156-5p 2.410880989 17.12610068 4.964394851
hsa-miR-3162-5p 8.079116607 57.39137063 9.428341899
hsa-miR-3189-3p 1.562705153 11.10094023 3.595719016
hsa-miR-3191-5p 1.925673313 13.67934593 4.011269468
hsa-miR-3194-5p 1.967760055 13.97831621 3.966179414
hsa-miR-3195 6.693009447 47.54492409 8.629280443
hsa-miR-3196 6.794186938 48.2636555 8.739987987
hsa-miR-3198 5.172946014 36.74689652 6.457343715
hsa-miR-32-5p 2.221762751 15.7826673 3.814202968
hsa-miR-320a 6.064389577 43.07941657 8.039474417
hsa-miR-320b 7.151715081 50.80341711 9.20038125
hsa-miR-320c 8.230368171 58.46581168 9.951193434
hsa-miR-320d 7.725435848 54.87893956 9.428341899
hsa-miR-320e 7.356786278 52.26017503 9.166945457
hsa-miR-324-3p 5.300069944 37.64994285 6.488825654
hsa-miR-324-5p 4.49681939 31.94391675 5.468096887
hsa-miR-331-3p 7.044867749 50.04440902 8.494581071
hsa-miR-338-3p 2.500761434 17.76458161 3.872137461
hsa-miR-33a-5p 2.095408822 14.8850908 3.752587461
hsa-miR-340-5p 4.307660302 30.60019318 5.628631779
hsa-miR-342-3p 5.312297351 37.7368023 6.891326276
hsa-miR-345-5p 2.022335691 14.36600346 5.307697101
hsa-miR-3529-3p 3.279464699 23.2962319 4.97754762
hsa-miR-3610 2.916603406 20.71858536 6.233434393
hsa-miR-3613-3p 1.833489088 13.0244997 4.481761629
hsa-miR-362-3p 3.732515475 26.51455467 5.333142011
hsa-miR-362-5p 3.063632943 21.76303453 5.287277176
hsa-miR-3620 1.916020994 13.61077905 4.268604247
hsa-miR-3646 2.378256536 16.89434736 5.487612049
hsa-miR-3651 5.96417265 42.36750869 9.34381318
hsa-miR-3653 4.365243802 31.00924731 6.457343715
hsa-miR-3656 6.79527371 48.27137557 10.20739641
hsa-miR-365b-3p 7.351961072 52.22589835 8.449858467
hsa-miR-3665 9.552278389 67.85622439 12.88839682
hsa-miR-3667-5p 3.284815365 23.33424126 8.004693565
hsa-miR-3676-3p 3.64853392 25.9179775 4.602704884
hsa-miR-3679-5p 6.597281304 46.86490304 9.428341899
hsa-miR-3692-5p 1.749766601 12.42976285 4.393786163
hsa-miR-3713 1.783968337 12.67272067 3.779902166
hsa-miR-374a-5p 6.637281637 47.14905217 8.307345268
hsa-miR-375 2.79980384 19.8888799 4.314074629
hsa-miR-3917 1.810940875 12.86432465 3.562103075
hsa-miR-3935 2.140621 15.20626315 4.964394851
hsa-miR-3937 2.033564882 14.44577192 4.109507663
hsa-miR-3940-3p 1.514500304 10.75850894 3.814202968
hsa-miR-422a 2.052950141 14.58347839 4.314074629
hsa-miR-423-3p 2.172437369 15.43227611 3.652512778
hsa-miR-423-5p 5.293541426 37.60356641 6.81014592
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hsa-miR-425-3p 3.884924864 27.59722053 5.143929899
hsa-miR-425-5p 4.917363749 34.9313247 5.994724118
hsa-miR-4259 1.37179534 9.744780104 3.714713499
hsa-miR-4274 1.653315521 11.7446063 4.024114051
hsa-miR-4281 9.817200194 69.73814122 12.26005643
hsa-miR-4284 10.63253305 75.52999597 12.88839682
hsa-miR-4286 10.13008898 71.96079963 12.26005643
hsa-miR-4290 2.298701585 16.32921532 5.032584172
hsa-miR-4291 2.547862817 18.09917425 4.798541198
hsa-miR-4298 5.512091705 39.15607527 8.962374449
hsa-miR-4299 6.196038079 44.01460396 7.047227741
hsa-miR-4306 4.970258284 35.30706997 5.567690079
hsa-miR-4312 1.981447562 14.07554773 4.546875495
hsa-miR-4313 4.137015132 29.38798637 5.354448634
hsa-miR-4327 4.357748635 30.95600413 7.047227741
hsa-miR-449a 2.257026606 16.03317006 4.949522624
hsa-miR-449b-3p 2.841666032 20.18625506 5.164175203
hsa-miR-449c-3p 2.132960588 15.15184612 4.74185466
hsa-miR-450a-5p 1.62227387 11.52409669 4.097587661
hsa-miR-455-3p 4.859824581 34.52258549 6.72659457
hsa-miR-455-5p 2.852716444 20.26475353 5.523791743
hsa-miR-484 3.507815356 24.91835939 4.7701092
hsa-miR-485-3p 1.931620513 13.72159287 4.889324858
hsa-miR-491-3p 2.79097818 19.82618533 5.749949854
hsa-miR-494 8.283241846 58.84140877 9.2666837
hsa-miR-498 2.042204194 14.50714273 4.128734764
hsa-miR-500a-3p 2.531922596 17.98594019 4.393786163
hsa-miR-500a-5p 2.013446043 14.30285435 3.836693986
hsa-miR-502-3p 1.809240846 12.85224821 3.886555557
hsa-miR-502-5p 1.490801471 10.59016028 3.625588668
hsa-miR-505-3p 4.297800682 30.53015371 5.2540446
hsa-miR-505-5p 2.540686049 18.04819286 3.779902166
hsa-miR-513a-5p 3.157323374 22.42858035 5.994724118
hsa-miR-514b-3p 1.382131538 9.818205037 3.828411682
hsa-miR-514b-5p 1.902062062 13.51161941 4.646466678
hsa-miR-520b 2.658295224 18.88364952 6.317471652
hsa-miR-520e 2.203213737 15.65090125 4.660504415
hsa-miR-542-3p 1.510684728 10.73140435 3.537066614
hsa-miR-548c-5p 1.908237818 13.55548994 4.993857538
hsa-miR-548d-5p 1.665941498 11.83429706 5.077772801
hsa-miR-548q 1.884876552 13.38953924 4.033989956
hsa-miR-548y 1.590730845 11.30002548 4.798541198
hsa-miR-572 5.299110117 37.64312455 8.351444508
hsa-miR-574-3p 6.738285613 47.86655099 8.307345268
hsa-miR-574-5p 6.309902776 44.82346109 7.529016836
hsa-miR-575 5.508253983 39.12881336 7.360508577
hsa-miR-576-3p 1.441526988 10.24013065 4.481761629
hsa-miR-583 2.349409727 16.68942917 5.618428218
hsa-miR-584-5p 1.953219225 13.87502296 4.204958561
hsa-miR-590-5p 3.62519098 25.75215698 4.92801709
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hsa-miR-595 2.533720676 17.99871316 4.426959826
hsa-miR-601 2.495110907 17.72444214 5.523791743
hsa-miR-622 1.987259396 14.11683307 3.836693986
hsa-miR-623 2.102125464 14.93280361 4.565506063
hsa-miR-629-3p 2.576928339 18.3056461 4.74185466
hsa-miR-636 2.87515986 20.42418413 5.941433092
hsa-miR-638 7.871257032 55.914805 11.26571402
hsa-miR-654-3p 1.577967188 11.20935668 3.919572726
hsa-miR-654-5p 1.988699375 14.12706221 3.828411682
hsa-miR-660-5p 4.883626779 34.69166842 6.457343715
hsa-miR-670 2.181052967 15.49347847 3.652512778
hsa-miR-671-5p 3.572143416 25.37532464 8.389540218
hsa-miR-708-5p 2.188349404 15.54530994 5.052081488
hsa-miR-720 12.96589229 92.10540783 14.07723238
hsa-miR-744-5p 3.261608841 23.16938979 5.643112092
hsa-miR-762 6.884747527 48.90696795 9.023659859
hsa-miR-764 1.417116093 10.06672374 3.662623558
hsa-miR-765 2.803470829 19.91492897 6.256605335
hsa-miR-766-3p 3.844533615 27.31029447 5.889589913
hsa-miR-769-5p 1.776484643 12.61955898 4.024114051
hsa-miR-874 5.604346965 39.8114261 7.529016836
hsa-miR-892b 1.894749864 13.45967598 3.850146141
hsa-miR-937 2.072552938 14.72273017 4.576235395
hsa-miR-939 5.706233587 40.53519495 7.851199509
hsa-miR-940 6.790849694 48.23994883 8.696390017
hsa-miR-96-5p 4.977460703 35.35823356 6.773394597
Page 48 of 65
ScholarOne Support: (434) 964-4100
Stem Cells Translational Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
MICRORNAs COMMONLY EXPRESSED IN PRIMARY HUMAN HEPATOCYTES AND hESC - DERIVED HEPATOCYTES
Relative max. intensity (%) Times detected (%) Chromosome Band
33.80695194 54.54545455 22q13.31
36.90897916 90.90909091 19q13.41
26.65713942 18.18181818 9q22.32
28.65612962 18.18181818 20q13.33 /// 18q11.2
65.35646358 100 10q23.31
64.50413344 100 6q25.3
73.66380382 100 8q24.21
91.55490564 100 18q21.31
44.87722788 100 3q27.1
37.19433597 100 16p13.3
64.50413344 100 16p13.3
45.69673148 36.36363636 3p21.31
42.96019866 100 12q13.3
39.3081421 36.36363636 12q13.3
46.29696836 100 8q24.3
29.99473375 90.90909091 11q13.1
38.37840372 100 19p13.2
91.55490564 100 2q31.1
26.85117404 36.36363636 22q13.31
25.94624199 9.090909091 2q31.3
39.3081421 81.81818182 19q13.41
58.59795924 100 11q24.1 /// 21q21.1
47.92116392 72.72727273 9q34.3
70.68998485 100 11q21
63.32381836 100 17q25.3
67.79195098 100 6p21.31
41.65163006 100 2q21.3 /// 3p22.3
49.72886077 100 22q13.2
31.1329829 81.81818182 17p11.2
68.80569746 100 1p36.13
27.25460434 45.45454545 10q21.3
46.09447 100 4q34.3
29.7756702 27.27272727 6p12.2
37.88487587 100 3p21.1 /// 12q23.1
37.88487587 81.81818182 16q22.1
36.28862165 36.36363636 2q37.1
66.37535654 100 7p15.2
44.87722788 100 12q13.13
51.0145556 100 19q13.33
38.84355064 90.90909091 8q24.3
56.17816998 100 8q24.3
29.65226106 63.63636364 21q21.3
68.80569746 100 13q14.2 /// 3q25.33
39.81671929 90.90909091 13q31.3
49.72886077 100 1q32.1 /// 9q33.3
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35.35885099 90.90909091 1q32.1 /// 9q33.3
46.95273427 100 20q11.21
37.32299404 81.81818182 7q32.2
35.26541808 90.90909091 22q11.21
32.50806176 81.81818182 1p31.1
65.82745424 100 Xp11.23
29.0021455 36.36363636 19p13.3
35.1597707 100 3p21.31
29.87063401 18.18181818 16q24.1
36.37239634 100 20q13.33
75.6858563 100 10p12.31
39.81671929 100 17q11.2
56.03510751 100 1p13.3
48.95370121 100 4q26
37.32299404 36.36363636 3q13.33
34.08724862 72.72727273 14q32.33
33.48248264 36.36363636 1q32.2
31.02080922 72.72727273 13q31.3
91.55490564 100 17q23.1
59.32589791 90.90909091 11p15.5
26.77206232 9.090909091 15q13.3
55.5111026 90.90909091 4p15.31 /// 5q34
29.52354874 63.63636364 17p13.3
42.96019866 100 Xp11.3
41.65163006 100 Xq28
39.55102772 54.54545455 13q12.12
65.82745424 100 19p13.13
65.35646358 100 9q22.32
65.11894677 100 9q22.32 /// 19p13.13
57.96265499 100 7q22.1
62.3852184 100 3p22.2 /// 12q14.1
65.35646358 100 2q35
58.59795924 100 19p13.13
66.37535654 100 9q22.32
42.76518346 90.90909091 3q28
83.65920458 100 9q34.11
32.21274654 63.63636364 6q13
52.98148807 100 6q13
56.41050324 100 8q24.22
40.6103749 90.90909091 1p34.2 /// 6q13
31.8369514 72.72727273 1p34.2
48.95370121 100 1p34.2
27.01795066 45.45454545 9p21.3
37.19433597 45.45454545 9p21.3
28.49473079 27.27272727 1q44
36.1633607 100 2p24.3
41.44416096 72.72727273 2q11.2
29.10790666 36.36363636 3q29
31.2120028 36.36363636 4p16.1
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60.34269268 100 5q33.2
29.99473375 54.54545455 8p12
35.26541808 54.54545455 10q11.21 /// 18p11.21 /// 21q11.2
66.97582058 100 11q12.1
25.5427979 27.27272727 19p13.11
28.49473079 36.36363636 19q13.32
28.17442596 36.36363636 20q13.2
61.29955244 100 20q13.33
62.0859822 100 20q13.33
45.87083272 100 22q11.21 /// 12q13.13
27.09483559 45.45454545 9q31.3
57.10976563 100 8p21.3
65.35646358 100 1p13.1 /// 1q42.11
70.68998485 100 18q11.2 /// 18q11.2
66.97582058 100 13q14.11 /// Xq27.1
65.11894677 100 19q13.32
46.09447 100 17p13.1
38.84355064 90.90909091 17p13.1
60.34269268 100 12q22
27.50638306 54.54545455 17q25.3
26.65713942 45.45454545 22q13.2
39.98393738 90.90909091 5q35.3
48.95370121 100 14q32.2
37.70412365 54.54545455 14q32.2
35.35885099 90.90909091 15q26.1
44.280255 45.45454545 8q24.11
31.8369514 27.27272727 13q14.2
37.88487587 90.90909091 Xp11.23
37.55906726 72.72727273 Xp11.23
30.32275189 36.36363636 1q42.13
38.98217989 36.36363636 20q13.12
66.37535654 100 9q22.31
45.87083272 81.81818182 22q12.2
72.50996603 100 11q23.3
60.0249981 100 17q11.2
91.55490564 100 13q22.3
56.86269397 36.36363636 22q13.33
32.69609225 100 17p13.1
66.97582058 100 2q21.2
31.2120028 27.27272727 6q25.3
26.85117404 36.36363636 15q24.3
59.0126315 100 Xq13.2
30.64575844 63.63636364 2q35
25.30400138 36.36363636 1p36.11
35.26541808 36.36363636 16q12.2
29.19258242 36.36363636 Xp11.4
27.09483559 18.18181818 19p13.3
30.64575844 36.36363636 15q22.31
25.94624199 54.54545455 17q11.2
48.37702283 100 17q11.2
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36.54077564 100 3p21.31
42.58453621 100 3p21.31
26.38809533 9.090909091 1q23.2
28.58597446 27.27272727 4p16.1
87.09138348 100 5q35.2
91.55490564 100 7q11.23
87.09138348 100 8p23.1
35.74981245 54.54545455 9q22.2
34.08724862 45.45454545 9q22.32
63.66574202 100 11p15.5
50.06117362 100 11p15.3
39.55102772 100 13q32.3
32.29949875 36.36363636 15q23
38.03623107 100 15q24.2
50.06117362 90.90909091 21q22.11
35.1597707 45.45454545 5q11.2
36.68459158 72.72727273 5q11.2
33.68456621 45.45454545 5q11.2
29.10790666 18.18181818 Xq26.3 /// Xq26.3
47.78350169 90.90909091 9q32
39.23918846 45.45454545 9q32
33.88527711 90.90909091 16p13.11
34.73214569 36.36363636 14q32.31
40.84574084 72.72727273 9p21.3
65.82745424 100 14q32.31
29.32916537 36.36363636 19q13.42
31.2120028 63.63636364 Xp11.23
27.25460434 54.54545455 Xp11.23
27.60880444 36.36363636 Xp11.23
25.75498202 18.18181818 Xp11.23
37.32299404 100 Xq27.1
26.85117404 72.72727273 Xq27.1
42.58453621 81.81818182 Xq27.3 /// Xq27.3
27.1957696 9.090909091 Xq27.3
33.00696156 36.36363636 Xq27.3
44.87722788 36.36363636 19q13.42
33.10668099 36.36363636 19q13.42
25.12615065 18.18181818 Xq26.3
35.47471125 45.45454545 12q14.2
36.07081751 18.18181818 8q24.13 /// 17q24.2
28.65612962 36.36363636 10p13
34.08724862 18.18181818 14q21.3
59.32589791 100 4p15.33
59.0126315 100 4p14
53.48364391 100 4p14
52.286617 100 4q21.22
31.8369514 9.090909091 4q25
39.91145467 36.36363636 5q15
29.87063401 36.36363636 5q32
35.0070025 90.90909091 7q11.23
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31.44765752 54.54545455 7q36.3
39.23918846 36.36363636 9q33.3
27.25460434 36.36363636 13q31.3
32.43184414 36.36363636 13q32.3
33.68456621 54.54545455 15q23
42.20597439 54.54545455 17q25.1
80.02790407 100 19p13.2
27.84334748 27.27272727 14q32.31
27.1957696 36.36363636 14q32.31
45.87083272 100 Xp11.23
25.94624199 54.54545455 11p11.2
59.59651722 45.45454545 7q36.1
35.88831493 36.36363636 11q14.1
100 100 3q26.1
40.08680074 63.63636364 17p12
64.1010933 100 16p11.2
26.01806562 18.18181818 Xq23
44.4448537 54.54545455 1q23.1
41.83769761 90.90909091 Xq24
28.58597446 27.27272727 19q13.32
53.48364391 100 5q31.2
27.350164 36.36363636 Xq27.3
32.50806176 54.54545455 8q24.3
55.77232299 100 8q24.3
61.77627664 100 16p13.3
48.11595359 90.90909091 7q32.2
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Description
ACC=MI0000063; ID=hsa-let-7b
ACC=MI0000066; ID=hsa-let-7e
ACC=MI0000067; ID=hsa-let-7f-1
ACC=MI0000651; ID=hsa-mir-1-1 /// ACC=MI0000437; ID=hsa-mir-1-2
ACC=MI0000114; ID=hsa-mir-107
ACC=MI0006334; ID=hsa-mir-1202
ACC=MI0006340; ID=hsa-mir-1207
ACC=MI0000442; ID=hsa-mir-122
ACC=MI0003764; ID=hsa-mir-1224
ACC=MI0006311; ID=hsa-mir-1225
ACC=MI0006311; ID=hsa-mir-1225
ACC=MI0006313; ID=hsa-mir-1226
ACC=MI0006318; ID=hsa-mir-1228
ACC=MI0006318; ID=hsa-mir-1228
ACC=MI0006324; ID=hsa-mir-1234
ACC=MI0006327; ID=hsa-mir-1237
ACC=MI0006328; ID=hsa-mir-1238
ACC=MI0006381; ID=hsa-mir-1246
ACC=MI0006384; ID=hsa-mir-1249
ACC=MI0006392; ID=hsa-mir-1258
ACC=MI0000469; ID=hsa-mir-125a
ACC=MI0000446; ID=hsa-mir-125b-1 /// ACC=MI0000470; ID=hsa-mir-125b-2
ACC=MI0000471; ID=hsa-mir-126
ACC=MI0014197; ID=hsa-mir-1260b
ACC=MI0016748; ID=hsa-mir-1268b
ACC=MI0006415; ID=hsa-mir-1275
ACC=MI0000447; ID=hsa-mir-128-1 /// ACC=MI0000727; ID=hsa-mir-128-2
ACC=MI0006428; ID=hsa-mir-1281
ACC=MI0006432; ID=hsa-mir-1288
ACC=MI0006352; ID=hsa-mir-1290
ACC=MI0003780; ID=hsa-mir-1296
ACC=MI0006372; ID=hsa-mir-1305
ACC=MI0000822; ID=hsa-mir-133b
ACC=MI0000452; ID=hsa-mir-135a-1 /// ACC=MI0000453; ID=hsa-mir-135a-2
ACC=MI0000456; ID=hsa-mir-140
ACC=MI0007076; ID=hsa-mir-1471
ACC=MI0000253; ID=hsa-mir-148a
ACC=MI0000811; ID=hsa-mir-148b
ACC=MI0000479; ID=hsa-mir-150
ACC=MI0000809; ID=hsa-mir-151a
ACC=MI0000809; ID=hsa-mir-151a
ACC=MI0000681; ID=hsa-mir-155
ACC=MI0000070; ID=hsa-mir-16-1 /// ACC=MI0000115; ID=hsa-mir-16-2
ACC=MI0000071; ID=hsa-mir-17
ACC=MI0000289; ID=hsa-mir-181a-1 /// ACC=MI0000269; ID=hsa-mir-181a-2
Page 54 of 65
ScholarOne Support: (434) 964-4100
Stem Cells Translational Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
ACC=MI0000270; ID=hsa-mir-181b-1 /// ACC=MI0000683; ID=hsa-mir-181b-2
ACC=MI0008193; ID=hsa-mir-1825
ACC=MI0000273; ID=hsa-mir-183
ACC=MI0000482; ID=hsa-mir-185
ACC=MI0000483; ID=hsa-mir-186
ACC=MI0000484; ID=hsa-mir-188
ACC=MI0008330; ID=hsa-mir-1909
ACC=MI0000465; ID=hsa-mir-191
ACC=MI0008331; ID=hsa-mir-1910
ACC=MI0008335; ID=hsa-mir-1914
ACC=MI0008336; ID=hsa-mir-1915
ACC=MI0000487; ID=hsa-mir-193a
ACC=MI0000239; ID=hsa-mir-197
ACC=MI0009983; ID=hsa-mir-1973
ACC=MI0000240; ID=hsa-mir-198
ACC=MI0000283; ID=hsa-mir-203
ACC=MI0000285; ID=hsa-mir-205
ACC=MI0000076; ID=hsa-mir-20a
ACC=MI0000077; ID=hsa-mir-21
ACC=MI0000286; ID=hsa-mir-210
ACC=MI0000287; ID=hsa-mir-211
ACC=MI0000294; ID=hsa-mir-218-1 /// ACC=MI0000295; ID=hsa-mir-218-2
ACC=MI0000078; ID=hsa-mir-22
ACC=MI0000298; ID=hsa-mir-221
ACC=MI0000301; ID=hsa-mir-224
ACC=MI0011282; ID=hsa-mir-2276
ACC=MI0000079; ID=hsa-mir-23a
ACC=MI0000439; ID=hsa-mir-23b
ACC=MI0000080; ID=hsa-mir-24-1 /// ACC=MI0000081; ID=hsa-mir-24-2
ACC=MI0000082; ID=hsa-mir-25
ACC=MI0000083; ID=hsa-mir-26a-1 /// ACC=MI0000750; ID=hsa-mir-26a-2
ACC=MI0000084; ID=hsa-mir-26b
ACC=MI0000085; ID=hsa-mir-27a
ACC=MI0000440; ID=hsa-mir-27b
ACC=MI0000086; ID=hsa-mir-28
ACC=MI0013006; ID=hsa-mir-2861
ACC=MI0000088; ID=hsa-mir-30a
ACC=MI0000088; ID=hsa-mir-30a
ACC=MI0000441; ID=hsa-mir-30b
ACC=MI0000736; ID=hsa-mir-30c-1 /// ACC=MI0000254; ID=hsa-mir-30c-2
ACC=MI0000749; ID=hsa-mir-30e
ACC=MI0000749; ID=hsa-mir-30e
ACC=MI0000089; ID=hsa-mir-31
ACC=MI0000089; ID=hsa-mir-31
ACC=MI0014140; ID=hsa-mir-3124
ACC=MI0014142; ID=hsa-mir-3125
ACC=MI0014144; ID=hsa-mir-3127
ACC=MI0014160; ID=hsa-mir-3137
ACC=MI0014161; ID=hsa-mir-3138
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ACC=MI0014165; ID=hsa-mir-3141
ACC=MI0014175; ID=hsa-mir-3148
ACC=MI0014184; ID=hsa-mir-3156-1 /// ACC=MI0014230; ID=hsa-mir-3156-2 /// ACC=MI0014242; ID=hsa-mir-3156-3
ACC=MI0014192; ID=hsa-mir-3162
ACC=MI0014233; ID=hsa-mir-3189
ACC=MI0014236; ID=hsa-mir-3191
ACC=MI0014239; ID=hsa-mir-3194
ACC=MI0014240; ID=hsa-mir-3195
ACC=MI0014241; ID=hsa-mir-3196
ACC=MI0014246; ID=hsa-mir-3198-1 /// ACC=MI0017335; ID=hsa-mir-3198-2
ACC=MI0000090; ID=hsa-mir-32
ACC=MI0000542; ID=hsa-mir-320a
ACC=MI0003776; ID=hsa-mir-320b-1 /// ACC=MI0003839; ID=hsa-mir-320b-2
ACC=MI0003778; ID=hsa-mir-320c-1 /// ACC=MI0008191; ID=hsa-mir-320c-2
ACC=MI0008190; ID=hsa-mir-320d-1 /// ACC=MI0008192; ID=hsa-mir-320d-2
ACC=MI0014234; ID=hsa-mir-320e
ACC=MI0000813; ID=hsa-mir-324
ACC=MI0000813; ID=hsa-mir-324
ACC=MI0000812; ID=hsa-mir-331
ACC=MI0000814; ID=hsa-mir-338
ACC=MI0000091; ID=hsa-mir-33a
ACC=MI0000802; ID=hsa-mir-340
ACC=MI0000805; ID=hsa-mir-342
ACC=MI0000825; ID=hsa-mir-345
ACC=MI0017351; ID=hsa-mir-3529
ACC=MI0016000; ID=hsa-mir-3610
ACC=MI0016003; ID=hsa-mir-3613
ACC=MI0000762; ID=hsa-mir-362
ACC=MI0000762; ID=hsa-mir-362
ACC=MI0016011; ID=hsa-mir-3620
ACC=MI0016046; ID=hsa-mir-3646
ACC=MI0016051; ID=hsa-mir-3651
ACC=MI0016053; ID=hsa-mir-3653
ACC=MI0016056; ID=hsa-mir-3656
ACC=MI0000769; ID=hsa-mir-365b
ACC=MI0016066; ID=hsa-mir-3665
ACC=MI0016068; ID=hsa-mir-3667
ACC=MI0016077; ID=hsa-mir-3676
ACC=MI0016080; ID=hsa-mir-3679
ACC=MI0016093; ID=hsa-mir-3692
ACC=MI0016134; ID=hsa-mir-3713
ACC=MI0000782; ID=hsa-mir-374a
ACC=MI0000783; ID=hsa-mir-375
ACC=MI0016423; ID=hsa-mir-3917
ACC=MI0016591; ID=hsa-mir-3935
ACC=MI0016593; ID=hsa-mir-3937
ACC=MI0016597; ID=hsa-mir-3940
ACC=MI0001444; ID=hsa-mir-422a
ACC=MI0001445; ID=hsa-mir-423
ACC=MI0001445; ID=hsa-mir-423
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ACC=MI0001448; ID=hsa-mir-425
ACC=MI0001448; ID=hsa-mir-425
ACC=MI0015858; ID=hsa-mir-4259
ACC=MI0015884; ID=hsa-mir-4274
ACC=MI0015885; ID=hsa-mir-4281
ACC=MI0015893; ID=hsa-mir-4284
ACC=MI0015894; ID=hsa-mir-4286
ACC=MI0015899; ID=hsa-mir-4290
ACC=MI0015900; ID=hsa-mir-4291
ACC=MI0015830; ID=hsa-mir-4298
ACC=MI0015829; ID=hsa-mir-4299
ACC=MI0015836; ID=hsa-mir-4306
ACC=MI0015842; ID=hsa-mir-4312
ACC=MI0015843; ID=hsa-mir-4313
ACC=MI0015867; ID=hsa-mir-4327
ACC=MI0001648; ID=hsa-mir-449a
ACC=MI0003673; ID=hsa-mir-449b
ACC=MI0003823; ID=hsa-mir-449c
ACC=MI0001652; ID=hsa-mir-450a-1 /// ACC=MI0003187; ID=hsa-mir-450a-2
ACC=MI0003513; ID=hsa-mir-455
ACC=MI0003513; ID=hsa-mir-455
ACC=MI0002468; ID=hsa-mir-484
ACC=MI0002469; ID=hsa-mir-485
ACC=MI0003126; ID=hsa-mir-491
ACC=MI0003134; ID=hsa-mir-494
ACC=MI0003142; ID=hsa-mir-498
ACC=MI0003184; ID=hsa-mir-500a
ACC=MI0003184; ID=hsa-mir-500a
ACC=MI0003186; ID=hsa-mir-502
ACC=MI0003186; ID=hsa-mir-502
ACC=MI0003190; ID=hsa-mir-505
ACC=MI0003190; ID=hsa-mir-505
ACC=MI0003191; ID=hsa-mir-513a-1 /// ACC=MI0003192; ID=hsa-mir-513a-2
ACC=MI0014251; ID=hsa-mir-514b
ACC=MI0014251; ID=hsa-mir-514b
ACC=MI0003155; ID=hsa-mir-520b
ACC=MI0003143; ID=hsa-mir-520e
ACC=MI0003686; ID=hsa-mir-542
ACC=MI0003630; ID=hsa-mir-548c
ACC=MI0003668; ID=hsa-mir-548d-1 /// ACC=MI0003671; ID=hsa-mir-548d-2
ACC=MI0010637; ID=hsa-mir-548q
ACC=MI0016595; ID=hsa-mir-548y
ACC=MI0003579; ID=hsa-mir-572
ACC=MI0003581; ID=hsa-mir-574
ACC=MI0003581; ID=hsa-mir-574
ACC=MI0003582; ID=hsa-mir-575
ACC=MI0003583; ID=hsa-mir-576
ACC=MI0003590; ID=hsa-mir-583
ACC=MI0003591; ID=hsa-mir-584
ACC=MI0003602; ID=hsa-mir-590
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ACC=MI0003607; ID=hsa-mir-595
ACC=MI0003614; ID=hsa-mir-601
ACC=MI0003636; ID=hsa-mir-622
ACC=MI0003637; ID=hsa-mir-623
ACC=MI0003643; ID=hsa-mir-629
ACC=MI0003651; ID=hsa-mir-636
ACC=MI0003653; ID=hsa-mir-638
ACC=MI0003676; ID=hsa-mir-654
ACC=MI0003676; ID=hsa-mir-654
ACC=MI0003684; ID=hsa-mir-660
ACC=MI0003933; ID=hsa-mir-670
ACC=MI0003760; ID=hsa-mir-671
ACC=MI0005543; ID=hsa-mir-708
ACC=MI0006654; ID=hsa-mir-720
ACC=MI0005559; ID=hsa-mir-744
ACC=MI0003892; ID=hsa-mir-762
ACC=MI0003944; ID=hsa-mir-764
ACC=MI0005116; ID=hsa-mir-765
ACC=MI0003836; ID=hsa-mir-766
ACC=MI0003834; ID=hsa-mir-769
ACC=MI0005532; ID=hsa-mir-874
ACC=MI0005538; ID=hsa-mir-892b
ACC=MI0005759; ID=hsa-mir-937
ACC=MI0005761; ID=hsa-mir-939
ACC=MI0005762; ID=hsa-mir-940
ACC=MI0000098; ID=hsa-mir-96
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ACC=MI0014184; ID=hsa-mir-3156-1 /// ACC=MI0014230; ID=hsa-mir-3156-2 /// ACC=MI0014242; ID=hsa-mir-3156-3
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Supplementary Table 3 
 
A) 
mRNA/microRNA 
Predicted consequential pairing of target region 
(top) and microRNA (bottom) 
 
Position 639-645 of SULT2A1 3' UTR 
 
hsa-miR-324-5p 
5' ...AGGGUUCAAAGCCCA--GGGAUGCA... 
                ||||   |||||||  
3'      UGUGGUUACGGGAUCCCCUACGC 
 
mRNA/microRNA 
Predicted consequential pairing of target region 
(top) and microRNA (bottom) 
 
 
B) 
Gene/ microRNA Seed Match Context + score percentile 
SULT2A1/ hsa-miR- 324-5p 8mer 96 
GSTT1/ has-miR-24-3p 7mer-m8 84 
 
C) 
microRNA/ Gene 
(symbol) 
Accession Number  (miRBase)  
hsa-miR-324-5p MI0000813 / MIMAT0000761  
hsa-miR-24-3p MI0000080 / MIMAT0000080  
 
 UniGene GeneBank 
SULT2A1 Hs.515835 NM_003167 
GSTT1 Hs.268573 NM_000853 
 
  
Position 266-272 of GSTT1 3' UTR 
 
hsa-miR-24 
5'   ...AAACCUGGGCUCAGCCUGAGCCU... 
           ||||        |||||||  
3'    GACAAGGACGACUU---GACUCGGU 
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Supplementary Table 4 
 
 
Name Host Dilution Source 
Primary Antibody 
SULT2A1 Rabbit polyclonal 1:250 Abcam 
GSTT1 Rabbit polyclonal 1:500 Abcam 
ABCG2 Mouse monoclonal 1:100 Abcam 
ABCC1 Mouse monoclonal 1:50 Abcam 
Secondary Antibody 
Alexa Fluor  568  Goat  1:400 Invitrogen 
Alexa Fluor  488  Rabbit 1:400 Invitrogen 
 
Name  Ref Number   Source  
Genes 
SULT2A1 Hs00234219_m1 (Taqman)  Applied Biosystems 
GSTT1 Hs00184475_m1 (Taqman)  Applied Biosystems 
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Supplementary Table 5 
A) 
 
B)  
THE NORMAL RANGES 
NAME RANGE (UNIT) 
ALT 10-50 (IU/L) 
CREATININE 30-120 (umol/L) 
BILIRUBIN 3-17 (umol/L) 
INR 0.8-1.2 (RATIO) 
 
 
 
 
 
 
 
STUDY NO. AGE OUTCOME ALT (IU/L) CREATININE 
(umol/L) 
BILIRUBIN 
(umol/L) 
INR RATIO 
(ratio) 
1 29 Died 8696 241 64 11.5 
8 38 Survived 5699 272 77 8.7 
58 33 Survived 9424 216 48 3 
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